Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Jun 29, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a medication called camrelizumab for patients with unresectable hepatocellular carcinoma (HCC), which is a type of liver cancer that cannot be surgically removed. HCC is a significant health concern in China, being the second leading cause of cancer deaths. Camrelizumab works by helping the body's immune system fight the cancer by blocking a protein that allows tumor cells to escape detection. This study aims to understand how safe and effective camrelizumab is for patients with HCC in real-world settings.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of HCC. However, pregnant or breastfeeding women and those involved in other clinical trials will not be eligible. Participants will have the opportunity to receive camrelizumab and will be monitored closely to see how well the treatment works and if there are any side effects. This study is important because it may provide valuable information on how to better treat patients with advanced liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Volunteer to participate in this study and sign an informed consent form; 2. Age ≥ 18 years; 3. Hepatocellular carcinoma confirmed/clinically confirmed by histopathology, cytology or imaging
• Exclusion Criteria:
• • 1. Documented pregnant or breastfeeding women;
• • 2. Patients who are participating in any interventional trials beyond clinical practice.